The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer

DFS of enrolled patients for 2 years

This study plans to enroll 80 patients with locally advanced cervical cancer (stage IB-ⅣA)
 confirmed by histology or cytology (according to the 2018 FIGO staging standard), who are
 expected to receive surgical resection or curative radiotherapy and chemotherapy. Collect
 baseline tumor tissue samples from patients during the treatment period, as well as
 peripheral blood samples (20 ml/time) from multiple treatment timepoints. Mutations in tumor
 tissue were detected by the 1021 genes panel, then personalized MRD monitoring probes were
 customized for patients, allowing for multi node peripheral blood sample ctDNA detection of
 enrolled patients. The clinical significance of ctDNA in prognostic stratification,
 recurrence monitoring, and efficacy prediction in surgical/non-surgical cervical cancer
 patients was explored. And compare the consistency and differences between ctDNA detection
 technology, imaging, and blood tumor markers in monitoring tumor disease progression, and
 evaluate the correlation between ctDNA status after curative treatment and patient PFS and
 RFS.